Taiho wins European endorsement for new gastric cancer drug; Repros shares jump on Proellex safety data;

@FierceBiotech: Struggling ARYx terminates staff, vows to get back on track. Article | Follow @FierceBiotech

 @JohnCFierce: Impax will get $11.5M upfront and up to $175M in milestones from GSK on Parkinson's drug pact. Story | Follow @JohnCFierce

> A group of EMA experts has recommended approval of Teysuno, a new therapy for gastric cancer developed by Taiho Pharmaceutical. "The CHMP recommendation also represents the first regulatory milestone for Taiho outside of Japan and Asia," says Taiho President Toru Usami, who plans to land a European partner for the therapy. Taiho release

> Shares of Repros Therapeutics jumped yesterday after the developer announced that no signs of liver toxicity were apparent after investigators tested a low dose of Proellex, which is designed to treat uterine fibroids and endometriosis. Story

> Norway's DiaGenic ASA will collaborate with Pfizer on a program to identify biomarkers in early stages of Alzheimer's disease. DiaGenic release

> Worcester, MA-based RXi Pharmaceuticals says that it had selected its first RNAi therapeutic product candidate to advance into development. RXi release

> A fledgling Harvard spinout that styles itself as the future "eBay of biomarkers" has raised $3 million, according to a report in MassHighTech. Story

> A translational team of experts in Europe say they have identified a protein which is produced naturally in the human body and can be used as a therapeutic vaccine capable of fighting a range of inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and allergic asthma. Story

> Want the next blockbuster drug? It's all in the delivery. Report

> Counterfeit drugs have made their way onto President Obama's priority list. And he's rolling out the big guns: leadership from Homeland Security, the Justice Department and Immigration and Customs Enforcement. Story

> Cambridge, MA-based Semprus Biosciences has added $18 million in equity financing to its coffers to support technology that helps improve the long-term performance of devices. Report

And Finally... In a first, scientists were able to use brain scanning technology to track the development of Alzheimer's from an early stage, helping shed light on new efforts to find a therapy that can slow or prevent the disease. Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.